A Case Report of Ropeginterferon Alfa-2b for Polycythemia Vera during Pregnancy

A Case Report of Ropeginterferon Alfa-2b for Polycythemia Vera during Pregnancy

Myeloproliferative neoplasms (MPN) such as essential thrombocythemia (ET) and polycythemia vera (PV) are rare during pregnancy. However, they are harmful because they are associated with an increased risk of thromboembolic, hemorrhagic, or microcirculatory disturbances or placental dysfunction leadi...

Full description

Bibliographic Details
Main Authors:	Su-Yeon Bang, Sung-Eun Lee
Format:	Article
Language:	English
Published:	MDPI AG 2023-03-01
Series:	Hematology Reports
Subjects:	case report myeloproliferative neoplasms polycythemia vera pregnancy ropeginterferon alfa-2b interferon
Online Access:	https://www.mdpi.com/2038-8330/15/1/18

Similar Items

Cost–effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera
by: Aaron T Gerds, et al.
Published: (2023-08-01)

An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future
by: Albert Qin, et al.
Published: (2023-01-01)

Ropeginterferon alfa-2b treatment in a young patient with multi-refractory polycythemia vera and double JAK2 gene mutation: a case report
by: Silvio Ligia, et al.
Published: (2024-01-01)

Use of Interferon Alfa in the Treatment of Myeloproliferative Neoplasms: Perspectives and Review of the Literature
by: Joan How, et al.
Published: (2020-07-01)

Treatment outcome and germline predictive factors of ropeginterferon alpha‐2b in myeloproliferative neoplasm patients
by: Chih‐Cheng Chen, et al.
Published: (2024-04-01)

Diagnosis and Management of Cardiovascular Risk in Patients with Polycythemia Vera
by: Benevolo G, et al.
Published: (2023-11-01)

A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera
by: Jie Jin, et al.
Published: (2023-06-01)

Are patients with high-risk polycythemia vera receiving cytoreductive medications? A retrospective analysis of real-world data
by: Dilan Paranagama, et al.
Published: (2018-07-01)

Ruxolitinib: a targeted treatment option for patients with polycythemia vera
by: Vaddi K, et al.
Published: (2016-05-01)

The role of erythropoietin levels and other hematological factors in the diagnosis of polycythemia vera in Iraqi patients
by: Aseel Modhfer Al Dayyeni, et al.
Published: (2023-01-01)

Osteolytic lesion in polycythemia vera: First report and review of literature
by: Verna Cheung, et al.
Published: (2022-05-01)

Obstructive Sleep Apnea Does Not Exclude Polycythemia Vera: A Case Report
by: Mohammad S. Afana, et al.
Published: (2024-01-01)

Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives
by: Hans Hasselbalch, et al.
Published: (2022-11-01)

Genetic Background of Polycythemia Vera
by: Mathilde Regimbeau, et al.
Published: (2022-04-01)

Whole-exome sequencing identifies novel candidate predisposition genes for familial polycythemia vera
by: Elina A. M. Hirvonen, et al.
Published: (2017-04-01)

Parathyroid Adenoma as a Rare Cause of Persistent Hypercalcemia in a Female with Polycythemia Vera
by: Ahmed M. Abdalhadi, et al.
Published: (2020-05-01)

Ropeginterferon alfa‐2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy
by: Hsien‐Hong Lin, et al.
Published: (2021-08-01)

Clinical features of children with polycythemia vera, essential thrombocythemia, and primary myelofibrosis in Japan: A retrospective nationwide survey
by: Hisashi Ishida, et al.
Published: (2020-07-01)

Polycythemia Vera in Pregnancy: A Descriptive Review of the Literature
by: Nicole Xu, et al.
Published: (2023-04-01)

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) arising in the setting of polycythemia vera (PV): An illustration of the emerging role of flow cytometry analysis in monitoring progression of myeloproliferative neoplasms
by: Siba El Hussein, et al.
Published: (2022-08-01)

Change in Polycythemia Vera Treatment: Ropeginterferon Alfa-2b in Light of Current Trials
by: Heinz Gisslinger
Published: (2023-12-01)

Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study
by: Francesca Palandri, et al.
Published: (2023-07-01)

Prevalence and clinical outcomes of polycythemia vera and essential thrombocythemia with hydroxyurea resistance or intolerance
by: Kittitat Chiaranairungrot, et al.
Published: (2022-12-01)

JAK2V617F positive polycythemia vera with paroxysmal nocturnal hemoglobinuria and visceral thromboses: a case report and review of the literature
by: Sevastianos Chatzidavid, et al.
Published: (2021-03-01)

Splenic infarction secondary to polycythemia Vera: Case report and literature review
by: Qusay Abdoh, PhD, et al.
Published: (2023-10-01)

Increased von Willebrand factor levels in polycythemia vera and phenotypic differences with essential thrombocythemia
by: Monica Sacco, et al.
Published: (2020-03-01)

Development of multiple myeloma after 15 years of treatment for polycythemia vera and successful treatment using bortezomib: A case report
by: Hideo Kimura, et al.
Published: (2022-11-01)

Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV)
by: Lucia Masarova, et al.
Published: (2017-11-01)

Red Blood Cell Morphodynamics in Patients with Polycythemia Vera and Stroke
by: Polina I. Kuznetsova, et al.
Published: (2022-02-01)

A Pilot Study of FDG-PET/CT in Polycythemia Vera Using Global Analysis Techniques
by: Cyrus Ayubcha, et al.
Published: (2020-01-01)

Portal vein thrombosis and Budd-Chiari syndrome as onset of polycythemia vera
by: Aurelio Seidita, et al.
Published: (2013-09-01)

Intermittent retinal artery occlusions as the first clinical manifestation of polycythemia vera: a case report
by: Jasmin Regensburger, et al.
Published: (2022-05-01)

The utility of testing erythropoietin level in polycythemia diagnosis
by: Abdellatif Ismail, et al.
Published: (2023-12-01)

Interferon-Alpha 2-a and Its Dual Effect in Treating Two Diseases (Hepatitis C and Polycythemia Vera)
by: Hawraa Shwaylia, et al.
Published: (2021-06-01)

Complete hematological and major molecular response through treatment with low‐dose Interferon alpha 2a in high‐risk polycythemia vera patient: a case report
by: Christoph Driessen, et al.
Published: (2021-10-01)

A remarkable hematological and molecular response pattern in a patient with polycythemia vera during combination therapy with simvastatin and alendronate
by: Anders Lindholm Sørensen, et al.
Published: (2016-01-01)

New Perspectives on Polycythemia Vera: From Diagnosis to Therapy
by: Alessandra Iurlo, et al.
Published: (2020-08-01)

Polycythemia vera: Perioperative anesthetic challenges and review of literature
by: Suman Saini, et al.
Published: (2019-01-01)

Can pegylated interferon improve the outcome of polycythemia vera patients?
by: Elena Crisà, et al.
Published: (2017-01-01)

When hemolysis masks polycythemia vera
by: Coralie Derrieux, et al.
Published: (2019-03-01)